Edwards Lifesciences' Stock Performance Amidst Medicare's Health Tech Spending Test

Edwards Lifesciences’ Stock Performance Amidst Medicare’s Health Tech Spending Test

As of July 6, 2026, Edwards Lifesciences (NYSE: EW) closed at $95.18, marking a 0.87% increase from the previous close. This uptick coincides with Medicare’s recent announcement of the ACCESS payment model, a pilot program evaluating the impact of health technology, particularly AI-driven solutions, on medical costs and care quality.

Medicare’s ACCESS Payment Model

Medicare’s ACCESS model, launched on July 2, 2026, involves over 150 healthcare organizations. It aims to transition from traditional fee-for-service payments to an outcomes-based approach, assessing whether health technologies can reduce costs while enhancing care quality. However, the reimbursement rates under ACCESS are lower than anticipated, potentially deterring some digital health firms reliant on labor-intensive models.

Potential Implications for Edwards Lifesciences

Edwards Lifesciences, a leader in structural heart innovations, may experience indirect effects from the ACCESS model. While the program primarily targets AI-driven health technologies, its emphasis on cost reduction and quality improvement aligns with Edwards’ mission. The company’s focus on transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) positions it well in a healthcare landscape increasingly valuing innovative, cost-effective solutions.

Recent Financial Performance

In Q4 2025, Edwards reported a 13.3% increase in sales to $1.57 billion, with TAVR sales growing by 12% to $1.16 billion. TMTT sales surged over 40% to $156 million. The company expressed confidence in achieving 8–10% constant currency sales growth in 2026, with TMTT sales projected to grow 35–45% to $740–$780 million.

Market Response

The 0.87% increase in EW’s stock price on July 6, 2026, suggests investor optimism. This sentiment may be influenced by the company’s strong financial performance and the potential for increased adoption of its technologies under Medicare’s new model. However, the lower-than-expected reimbursement rates in the ACCESS program could pose challenges for companies relying on labor-intensive models.

Conclusion

Edwards Lifesciences’ recent stock performance reflects a complex interplay of factors, including Medicare’s ACCESS payment model and the company’s robust financial health. As the healthcare industry continues to evolve towards value-based care, Edwards’ innovative solutions may play a pivotal role in shaping future treatment paradigms.